Calamos Advisors
TARS icon

Calamos Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Calamos Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43,832
Closed -$3.07M – 1246
2026
Q1 		$3.07M Buy
43,832
+9,390
+27% +$656K 0.01% 615
2025
Q4 		$2.82M Buy
+34,442
New +$2.57M 0.01% 591
2024
Q3 		– Sell
-7,404
Closed -$201K – 992
2024
Q2 		$201K Sell
7,404
-2,474
-25% -$83.2K ﹤0.01% 787
2024
Q1 		$359K Buy
+9,878
New +$290K ﹤0.01% 715

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Calamos Advisors's TARS Position: Q2 2026 in Review

Calamos Advisors sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 43,832 shares — an estimated $3.07M sold.

Calamos Advisors first reported a position in TARS in Q1 2024 and held it in 4 quarters. The position peaked at $3.07M in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Calamos Advisors reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Calamos Advisors sold 43,832 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $3.07M.
  • Calamos Advisors first reported a position in Tarsus Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Calamos Advisors's Tarsus Pharmaceuticals position peaked at $3.07M in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.